Systematic review of vitamin D and hypertensive disorders of pregnancy by O'Callaghan, Karen M. & Kiely, Mairead E.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Systematic review of vitamin D and hypertensive disorders of pregnancy
Author(s) O'Callaghan, Karen M.; Kiely, Mairead E.
Publication date 2018
Original citation O’Callaghan, K. and Kiely, M. (2018) 'Systematic review of vitamin D
and hypertensive disorders of pregnancy', Nutrients, 10(3), 294 (18pp).
doi: 10.3390/nu10030294
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://www.mdpi.com/2072-6643/10/3/294
http://dx.doi.org/10.3390/nu10030294
Access to the full text of the published version may require a
subscription.
Rights © 2018, the Authors. Licensee MDPI, Basel, Switzerland. This
article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/).
http://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/5949
Downloaded on 2019-12-02T14:42:22Z
nutrients
Review
Systematic Review of Vitamin D and Hypertensive
Disorders of Pregnancy
Karen M. O’Callaghan 1,2 and Mairead Kiely 1,2,* ID
1 Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences,
University College Cork, Cork T12 Y337, Ireland; karen.ocallaghan@ucc.ie
2 Irish Centre for Fetal and Neonatal Translational Research (INFANT), University College Cork,
Cork T12 DFK4, Ireland
* Correspondence: m.kiely@ucc.ie; Tel.: +353-214-903-394
Received: 21 December 2017; Accepted: 27 February 2018; Published: 1 March 2018
Abstract: This narrative systematic review evaluates growing evidence of an association between low
maternal vitamin D status and increased risk of hypertensive disorders. The inclusion of interventional,
observational, and dietary studies on vitamin D and all hypertensive disorders of pregnancy is a
novel aspect of this review, providing a unique contribution to an intensively-researched area that
still lacks a definitive conclusion. To date, trial evidence supports a protective effect of combined
vitamin D and calcium supplementation against preeclampsia. Conflicting data for an association
of vitamin D with gestational hypertensive disorders in observational studies arises from a number
of sources, including large heterogeneity between study designs, lack of adherence to standardized
perinatal outcome definitions, variable quality of analytical data for 25-hydroxyvitamin D (25(OH)D),
and inconsistent data reporting of vitamin D status. While evidence does appear to lean towards an
increased risk of gestational hypertensive disorders at 25(OH)D concentrations <50 nmol/L, caution
should be exercised with dosing in trials, given the lack of data on long-term safety. The possibility
that a fairly narrow target range for circulating 25(OH)D for achievement of clinically-relevant
improvements requires further exploration. As hypertension alone, and not preeclampsia specifically,
limits intrauterine growth, evaluation of the relationship between vitamin D status and all terms of
hypertension in pregnancy is a clinically relevant area for research and should be prioritised in future
randomised trials.
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1. Introduction
Hypertensive disorders of pregnancy are a major cause of maternal and foetal severe acute
morbidity, long-term disability, and mortality. On a global basis, an estimated 10% of pregnant women
suffer from hypertensive disorders, representing a serious threat to public health [1]. Hypertension in
pregnancy can be classified by the terms chronic hypertension, gestational hypertension, preeclampsia
(PE), or chronic hypertension with superimposed PE [2]. Chronic hypertension refers to a systolic
blood pressure (SBP) ≥ 140 mmHg and/or a diastolic blood pressure (DBP) ≥90 mmHg, on at least
two occasions, 4 h apart, which predates pregnancy or occurs before the 20th week of gestation. If this
hypertension develops after 20 gestational weeks, it is referred to as gestational hypertension or
pregnancy-induced hypertension (PIH). The presence of proteinuria has been a long-standing criterion
used to distinguish PE from PIH. However, proteinuria has been questioned as a prerequisite in recent
years [3], and new diagnostic criteria allow for the identification of PE based on new onset hypertension
in the absence of proteinuria, but in combination with haematological abnormalities, renal and liver
impairment, neurological symptoms, and uteroplacental dysregulation [2,3]. Where PE occurs in
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women with longstanding hypertension, this is termed chronic hypertension with superimposed
PE [2].
Affecting an estimated 3–5% of pregnancies worldwide [4], PE is a heterogeneous disorder that is
alleviated only after delivery of the placenta [5]. Globally, PE accounts for more than 70,000 maternal
and over 500,000 infantile deaths per annum [6], and treatment of PE in nulliparous women results in
a yearly economic burden of €31 million in the developed world alone [7]. The etiology of PE is not
fully discerned and its rapid progression and multisystem involvement challenges the understanding
of both the pathogenesis of PE and the development of preventative measures [8]. Initiation of
PE is believed to stem from the immune rejection of cytotrophoblasts during placentation, causing
impaired remodelling of the spiral arteries of the decidua and myometrium [9]. In recent years,
the discovery of vitamin D-specific receptors and metabolites in the placenta and decidua [10] has
highlighted a potential role for vitamin D in perinatal health, outside of its established role in skeletal
mineralisation [11].
Maternal vitamin D metabolism is altered during pregnancy, leading to increased circulating levels
of both the vitamin D binding protein (VDBP) [12] and the active metabolite, 1,25-dihydroxyvitamin
D (1,25(OH)2D) [13]. At term, expectant mothers have almost twice the concentration of 1,25(OH)2D
compared to non-pregnant women [13], of which at least 50% is thought to be contributed by the
placenta and/or decidual tissue [10,14,15]. The precise function of this increase in 1,25(OH)2D has not
been fully established, but current concepts propose that the surge in 1,25(OH)2D is a physiological
response induced to permit immune tolerance through vitamin D pathways at the maternal-foetal
interface, thereby supporting proper placentation [16].
Widespread vitamin D deficiency has been reported among gravidae worldwide [17], and the
potential of vitamin D to prevent pregnancy-related complications is an area of current focus, however,
conclusive evidence from randomised trials to support a role for vitamin D in perinatal health
is still pending [18]. Women with PE have been shown to experience alterations in calcium and
vitamin D metabolism [19]. In comparison to the normal placenta, mRNA expression for the vitamin
D-metabolising enzymes CYP2R1, CYP27B1, CYP24A1, and the vitamin D receptor (VDR) have
been increased and decreased in placentas of women with PE [20–22], providing direct evidence
for disrupted vitamin D metabolic homeostasis in the preeclamptic placenta [22]. The underlying
mechanism for this disruption and its association with PE development is not fully understood. It is
hypothesised that low-circulating 1,25(OH)2D leads to an imbalance in immune function, resulting in a
shift towards a pro-inflammatory environment [16] and disrupted implantation [19]. Increased tumour
necrosis factor (TNF)-α stimulates catabolism of 1,25(OH)2D, contributing to the lower circulating
calcium levels that are observed in PE-diagnosed pregnancies [23,24]. To state that malplacentation
results principally from the pro-inflammatory environment induced by Th1 cytokine activity would be
considered a narrow interpretation, however, and it is likely that vitamin D may contribute to multiple
innate and adaptive immune responses in placental and decidual tissue [16]. Despite the advances
made in vitro, association studies of vitamin D and PIH can be difficult to interpret at a clinical level,
owing to the uncertainty of the pathogenesis of PE, alongside the multiple roles of vitamin D in
immune function [25].
2. Objectives
The purpose of this narrative systematic review was to investigate the association of vitamin D
and risk of hypertensive disorders in pregnancy. To date, most systematic reviews have focused on
one particular study design only (observational or intervention) [26–28], have specified vitamin D
status in the inclusion criteria but excluded studies reporting vitamin D intakes [26,27,29], or have
focused on PE but not on other forms of pregnancy-associated hypertension [26,27,29,30]. This review
aimed to critically evaluate the findings from both observational and interventional studies, in which
either vitamin D status or dietary intakes are assessed and includes all outcomes which fall under the
umbrella term of gestational hypertensive disorders. Owing to the mixed nature of the study design
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(observational or interventional), the marker of exposure (vitamin D intake or status) and the study
outcome (blood pressure, PIH or PE), we did not conduct a meta-analysis as part of this review.
2.1. PICO
Population: Apparently healthy women having an uncomplicated pregnancy, not diagnosed with
PIH prior to commencement of the study (with the exception of case-control designs) and for whom
vitamin D intake or status data is available.
Intervention and comparison: Vitamin D (ergocalciferol or cholecalciferol) versus placebo or dose
response. Dietary vitamin D intake and/or 25-hydroxyvitamin D (25(OH)D) status.
Outcome: Recorded blood pressure, PIH or PE (as defined by investigator) before onset or at time
of delivery.
2.2. Search Methods
The Medline (Pubmed) and EMBASE electronic databases were searched from inception to
11 November 2016. A structured search strategy was devised using key terms selected from the Medical
Subject Headings (MeSH) database and related text words for “vitamin D”, “vitamin D deficiency”,
“pregnancy”, “preeclampsia”, “hypertension”, and “blood pressure”. Where applicable, bibliographies
of selected papers were hand-searched for additional references and assessed for inclusion.
2.3. Inclusion Criteria
The following inclusion criteria were applied: full text articles published in the English language;
apparently healthy pregnancies before diagnosis of PIH; recorded blood pressure outcome; and studies
where the vitamin D intake or status of the mother during pregnancy was available. Studies measuring
25(OH)D specifically, and not 1,25(OH)2D, were included owing to the short half-life of 1,25(OH)2D,
making this metabolite unsuitable for accurately assessing vitamin D status.
2.4. Exclusion Criteria
Articles were excluded from the final review if they fell under any of the following categories:
postpartum maternal outcomes only; methodological validation papers or papers relating to
experimental techniques; genetic studies; animal or in vitro models excluding clinical data; studies
reporting biological mechanisms of vitamin D metabolism only; studies that focus solely on populations
with gestational diabetes mellitus and studies involving participants diagnosed with any pre-existing
metabolic disorder known to interfere with vitamin D metabolism, including chronic kidney disease
and liver or gastrointestinal disorders.
2.5. Data Collection
Titles and abstracts generated by the search strategy were screened independently by a single
reviewer (K.M.O.C.) and relevant articles were identified for further investigation. Studies were
included if they reported original data only. Letters, comments, and editorials were excluded,
in addition to duplicate articles and narrative review articles. The most recent comprehensive
systematic reviews were included, provided a meta-analysis was also reported. The full texts of
relevant abstracts were assessed and articles included in the final search were agreed following
discussions with a second reviewer (M.K.). To ensure uniformity, for studies reporting 25(OH)D
concentrations in ng/mL, values were converted to nmol/L by multiplying by a conversion factor
of 2.5, and vitamin D intakes expressed in µg/day were converted to IU/day, for which 1 µg is
equivalent to 40 IU. For observational studies reporting both vitamin D status and dietary intake, data
relating to 25(OH)D was prioritised in discussion. For intervention trials, the supplemental dose was
discussed in preference to achieved 25(OH)D concentrations, to allow for comparison between the
administered dose range, intervention duration and incidence of PIH.
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For clarity, in the absence of a universal consensus on deficiency and sufficiency thresholds
for serum 25(OH)D concentrations, throughout the text we used the Institute of Medicine-assigned
cut-offs of <30 nmol/L to define vitamin D deficiency, with low vitamin D status referring to values
<50 nmol/L [11], and have specified alternatives as appropriate.
3. Results
The initial search identified 190 papers from 1957 to 2016. Once duplicates were removed, 56 texts
remained after titles and abstracts were scanned for relevance. Ten papers were identified through
hand-searching bibliographies of relevant texts. Results were filtered according to the search criteria,
producing a final selection of 49 papers. Three recent systematic reviews and meta-analyses were
included, for which we excluded the individual studies incorporated in these reviews, unless they
reported an outcome of interest (e.g., vitamin D status or intake/PE or hypertension) that did not
feature in the meta-analysis. In this way, we achieved maximum coverage of potentially neglected
outcomes. In addition to the three systematic reviews, 34 studies were included in the final review,
consisting of three randomised controlled trials (RCT) and 31 observational studies.
A full description of the search strategy and selection process is provided in Figure 1.
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3.1. Intervention Studies
3.1.1. Preecla psia
In their updated ochrane syste atic revie of R Ts, e-Regil et al. [28] reported the effects of
vita in D interventions on several maternal and infant health outcomes, for which two studies focused
on PE. Including a small sample of 219 women, the combined analysis from both trials (one providing
400 IU/day, the other providing up to 4 doses of 120,000 IU across gestation) trended towards reduction
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of PE with supplementation (8.9% vs. 15.5%; average risk ratio 0.52; 95% confidence interval (CI):
0.25, 1.05) [28]. Using the GRADE (Grading of Recommendations, Assessment, Development, and
Evaluation) classification [31], this evidence was deemed of low quality, owing to reporting bias and/or
selection, detection, performance, and attrition bias of the two studies. An earlier meta-analysis by
Hyppönen and colleagues [30] involved four randomised trials of vitamin D supplementation during
pregnancy, of which three were placebo-controlled, unblinded studies (dose range 450–1000 IU/day)
and a fourth included a group receiving 400 IU/day as a comparator to the two treatment groups
(2000 and 4000 IU/day). This review differed from De-Regil [28] in that a placebo/zero intervention
group was not a prerequisite, therefore allowing inclusion of vitamin D dose-comparison studies.
A similar conclusion was reached of a reduced risk of PE (pooled odds ratio 0.66; 95% CI: 0.52, 0.83,
p = 0.001), among supplemented groups. Both meta-analyses highlight insufficient evidence to justify
setting a recommendation for supplemental vitamin D during pregnancy based on the avoidance
of PE.
With regard to combined vitamin D and calcium supplementation, the De-Regil et al. [28]
meta-analysis of three RCTs (n = 1114 women) showed a reduced risk of PE (5% vs. 9%; average risk
ratio 0.51; 95% CI: 0.32, 0.80) in supplemented groups. These studies had lower bias than the two small
vitamin D only RCTs and were rated as moderate quality evidence. Collectively, the trial evidence to
date supports the view that co-supplementation of vitamin D with calcium may reduce the risk of PE
more than supplemental vitamin D alone, although this comparison is not evenly matched in terms of
sample size or study quality.
3.1.2. Gestational Hypertension
While most published trials focus on development of PE, few have assessed the impact of
supplemental vitamin D on the risk of hypertension in pregnancy. We identified three recent trials of
vitamin D and gestational blood pressure. Beginning at week 25 of gestation, Asemi [32] noted that a
rise in both SBP (−0.2 ± 1.4 vs. 5.5 ± 1.6 mmHg, p = 0.01) and DBP (−0.4 ± 1.1 vs. 3.1 ± 1.1 mmHg,
p = 0.01) was prevented following 9 weeks of vitamin D supplementation (400 IU/day) compared
with placebo. This contrasts with findings of an open-label RCT by Hossain [33] in Pakistani women,
where supplemental vitamin D did not influence the risk of gestational hypertension relative to routine
antenatal care, at a dose corresponding to the current tolerable upper intake level (4000 IU/day) [11].
When the combination of vitamin D plus calcium supplementation was compared to placebo, SBP
was unaffected, but a significant decrease was observed for DBP (−1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg,
p = 0.02) [34], although in a small sample size (n = 46) and with a low supplemental dose (200 IU/day).
Careful consideration must be given to the sample populations of these 3 intervention studies.
In populations of poor socioeconomic status, with a high prevalence of low vitamin D status and
where both calcium and vitamin D intakes are likely to be low, correction of vitamin D and calcium
deficiency may reduce the incidence of adverse perinatal outcomes. However, the results may
not be generally applicable, but are important for vulnerable populations who would benefit from
nutritional intervention.
3.2. Observational Studies
3.2.1. Vitamin D Status and Preeclampsia
In 2013, Aghajafari et al. [26] published a systematic review and meta-analysis of observational
studies, including nine studies that focused on the association of maternal 25(OH)D status and
risk of PE. The combined analysis, using the most adjusted model, found PE to be significantly
associated with 25(OH)D concentrations <50 nmol/L (pooled odds ratio 1.79; 95% CI: 1.25, 2.58).
Heterogeneity between studies was a limiting factor in the meta-analysis, therefore urging caution in
the interpretation of the findings. The authors argued that, given the mechanistic underpinning and
biological plausibility of the associations between vitamin D and metabolic abnormalities including
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hypertension, plus the relative consistency in diverse populations where low 25(OH)D levels often
precede the adverse outcome (thus reducing the likelihood of reverse causation), their findings may
show a causal relationship if examined in appropriately-designed trials [26].
Following this meta-analysis, prospective observational studies continue to examine the role of
vitamin D in PE progression. Results from the large, multi-ethnic, seasonally-balanced GraviD study
suggest an increase in 25(OH)D concentrations of at least 30 nmol/L from the first to the final trimester
is associated with a lower odds of developing PE, irrespective of vitamin D status in early pregnancy.
The authors reasoned that 25(OH)D status at the beginning of gestation may not contribute to placental
development but that an increment in concentrations may help protect against the initiation of PE
as pregnancy progresses towards the latter stages [35]. A similar theory was reported by Wei [36],
whose longitudinal assessment of Canadian gravidae found low vitamin D status in the late, but not
early, second trimester was associated with a greater risk of PE. The 30 nmol/L increase in 25(OH)D
status associated with reduced odds of PE in GraviD corresponds to the observed seasonal variation
in vitamin D status in Sweden as well as a lower incidence of PE among women giving birth during
summer-autumn compared with winter-early spring [35]. Based on clinical or biochemical assessment,
the Evaluating Maternal Markers of Acquired risk of Preeclampsia (EMMA) study identified women
(n = 221) at high risk of PE in the first half of pregnancy who continued receiving routine antenatal care.
Despite the high prevalence (53%) of low vitamin D status, the subsequent risk of PE was not correlated
with maternal 25(OH)D [37]. Without measurement of 25(OH)D status at a time closer to delivery, it is
not possible to assess whether an increase in vitamin D status from early to late pregnancy would
overcome the acknowledged clinical and/or biochemical abnormalities in early pregnancy, therefore,
potentially contributing to the hypothesis described by Bärebring [35] and Wei [36]. The EMMA study
is also hampered by the heterogeneity of the study sample, in which 10% of women were diagnosed
with chronic hypertension at enrolment, introducing significant bias [37]. In a smaller (n = 75), less
affluent cohort, maternal vitamin D status at delivery was identified as an independent predictor of
PE diagnosis among women having a singleton pregnancy and attending a tertiary care facility in
Pakistan [38]. However, this sample was malnourished, with 45% having a 25(OH)D concentration
<25 nmol/L.
Among a large sample of well-characterised, low-risk nulliparous women, with a 17% prevalence
of 25(OH)D <30 nmol/L, we recently reported a 36% reduction in the composite outcome of PE
and small-for-gestational-age birth when 25(OH)D concentrations exceeded 75 nmol/L at 15 weeks’
gestation [39]. Similarly, the combination of two prospective cohorts in Canada found 25(OH)D
concentrations <30 nmol/L in early pregnancy led to a greater risk of developing PE when compared
to concentrations >50 nmol/L [40]. Scholl and colleagues [41] demonstrated a 2.86-fold increased
risk of PE in women with elevated parathyroid hormone levels when early pregnancy 25(OH)D
was <50 nmol/L. This observation led to the development of the “calcium-metabolic stress” concept,
whereby a dysregulation of calcium metabolism, resulting from inadequate dietary calcium and/or
low 25(OH)D status, causes secondary hyperparathyroidism in pregnancy which, in turn, increases
the risk of PE and hypertensive disorders [41].
In terms of analysing interactions between vitamin D and acknowledged risk factors for PE and
pregnancy-induced hypertension, maternal placental growth factor (PlGF) levels were low among
women presenting with low vitamin D status in the early and late second trimester [42]. Though both
variables were inversely related to PE risk, 25(OH)D and PlGF were not found to share a mutual causal
pathway in the development of PE. Therefore, whether the observed association between 25(OH)D
and PE risk is linked to impaired angiogenesis [42] is questionable. In a prospective study, biochemical
and/or biophysical markers of PE development did not differ among first trimester gravidae with or
without low vitamin D status [43]. Nonetheless, retrospective analysis has shown an increased risk of
late-onset, but not early-onset, PE among women with low vitamin D status at clinical presentation
despite no difference in first trimester 25(OH)D concentrations between PE complicated and non-PE
complicated pregnancies [44]. The decrease in 25(OH)D status in late pregnancy among the PE group
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contrasts to the increase observed for the undiagnosed group, again emphasising the possibility that
vitamin D is implicated in PE development in late gestation, independent of differences in the multiple
mechanistic pathways of PE pathogenesis in early pregnancy [44].
Apart from longitudinal studies, the relationship between reduced 25(OH)D status and placental
biomarkers of PE has been described by Woodham et al. [45] in their nested case-control study of
41 women diagnosed with PE, matched by race/ethnicity to 123 normotensive gravidae at term. In the
adjusted regression model, both 25(OH)D concentration and the soluble fms-like tyrosine kinase-1
(sFLT)/PlGF ratio at the beginning of the second trimester were identified as significant predictors
of severe PE, for which women experienced pulmonary oedema, seizures, oliguria, or symptoms of
hepatic or cerebral dysfunction, in addition to elevated blood pressure and proteinuria. For each
10 nmol/L increase in serum 25(OH)D, a 38% reduction in the odds of developing severe PE was
predicted. Similar to that observed in the cohort studies [42–44], no interaction was found between
25(OH)D status and developmental biomarkers of PE, therefore extending the theory that vitamin D
deficiency and angiogenic factors contribute to PE development through independent mechanistic
pathways. Nonetheless, Woodham [45] suggested that combining mid-gestational serum 25(OH)D
concentrations with the angiogenic activity factors sFLT and PlGF would yield a better prediction of
severe PE than either measure alone. In addition to placental biomarkers, the potential association
between vitamin D and markers of oxidative stress [46] and inflammation [47] has also been explored in
PE-diagnosed pregnancies at the nested case-control level, both reporting no interaction with 25(OH)D
and subsequent PE risk.
Other nested case-control studies provide weak evidence for an association between early
pregnancy vitamin D status and PE development, often concluding that low serum 25(OH)D alone
does not contribute to PE risk [48,49], even among large, well-characterised sample populations [50].
Subgroup analysis by season of blood collection has shown support for the correlation between low
summer time vitamin D status and PE [48]. However, deficiency during the summer months likely
indicates lower mean year-round 25(OH)D concentrations and it is plausible that the seasonal vitamin
D-PE relationship reflects an association of PE with vitamin D among those who consistently present
with low 25(OH)D status. Similarly, in the study by Lechtermann et al. [51], serum 25(OH)D levels
stratified by season at delivery were increased only among healthy women giving birth during the
summer months, but little response to seasonal variation in vitamin D status was observed for those
diagnosed with PE. Moreover, the lack of a seasonal elevation in vitamin D status among women
diagnosed with PE may inadvertently reflect lower outdoor physical activity levels, whereby risk
of developing a hypertensive disorder is highest among women who are least physically active.
In terms of vitamin D metabolism, the negative correlation between CYP27B1 and CYP24A1 that
occurs in healthy pregnancies was not evident in the preeclamptic placenta in Lechtermann’s study [51],
leading the authors to believe that the dysregulation of CYP24A1 in PE may contribute to the lack
of seasonal variation in 25(OH)D status among PE-complicated pregnancies. The small number
of patients included in the gene expression analysis (13 cases of PE and 14 controls) questions the
reliability of these findings and repetition of this analysis in a larger cohort is required. Though once
again limited by sample size (n = 48), the work by Anderson and colleagues [52] contrasts to that by
Lechtermann [51], in which altered placental gene expression of the VDR and CYP27B1 was identified
among women diagnosed with PE compared to controls, for which no difference in mean first trimester
25(OH)D concentrations were observed.
The proposed interplay between angiogenic factors, 25(OH)D concentrations and PE development
has also been explored in case-control studies. Despite an almost 50% decrease in median 25(OH)D
concentrations among patients with early onset severe PE (EOSPE) compared with gestational
age-matched controls, Robinson et al. [53] stressed that 25(OH)D status could not be identified as a
stand-alone diagnostic marker, yet deficiency may contribute to the placental modifications that occur
during the early stages of PE development. Regarding vitamin D status alone, a lower median 25(OH)D
concentration was found among preeclamptic mother-newborn dyads in Brazil [54], and mean serum
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25(OH)D concentrations were significantly reduced among PE-diagnosed Iranian women [55,56] and
their neonates [56] compared to controls; however, this is likely confounded by the low socioeconomic
status and higher risk of PE in deprived communities.
To our knowledge, only one study examined the association between maternal 25(OH)D status
and risk of eclampsia specifically [57]. Among a case-control analysis involving 33 diagnoses of PE
and 79 diagnoses of eclampsia compared to 76 controls, and following adjustment for age, body mass
index (BMI), and pregnancy duration, women with a third trimester plasma 25(OH)D concentration
<75 nmol/L exhibited a three- and five-fold increased risk of developing PE and eclampsia, respectively.
However, a cut-off of 75 nmol/L is a very conservative level to define vitamin D deficiency; only 12%
of women exceeded this threshold. Overall, there was evidence of poor nutritional status, indicated
by a low mean BMI (17.7 ± 2.6 kg/m2) and a low frequency of supplement use (23%) in the sample
population. Nonetheless, a comparison of women in the lowest quartile of 25(OH)D concentrations
(<30.1 nmol/L) to those in the highest quartile (>90.2 nmol/L) found the risk of eclampsia was 17 times
greater among women with vitamin D deficiency [57].
The classification of PE by category, as distinguished by mild (SBP ≥ 140 mmHg and/or
DBP ≥ 90 mmHg with proteinuria) or severe (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg with
elevated proteinuria, plus convulsions or end-organ damage and dysfunction) and its association with
vitamin D status, as described by Woodham [45] and Ullah [57], was later explored in two additional
case-control designs [58,59]. The analysis by Singla [59], of 74 preeclamptic nulliparous women and
100 controls in India, found maternal 25(OH)D concentrations were negatively associated with blood
pressure and risk of PE; however, the severity of PE was not related to vitamin D status. The high
prevalence (>80%) of low vitamin D status in this study indicates overall nutritional inadequacy,
which was poorly characterised, with no data on maternal anthropometry or prenatal supplement
use. It is plausible that the gravidae examined by both Ullah [57] and Singla [59] are at an increased
risk of adverse perinatal outcomes irrespective of vitamin D status and, therefore, we caution the
extrapolation of these findings to the wider obstetric population. Lastly, Bodnar [58] explored the
relationship of vitamin D status and PE risk using data from the multi-ethnic Collaborative Perinatal
Project, 1959–1966. Here, low vitamin D status was shown to be a risk factor for severe PE only, but
not for milder forms of the disease. PE was most often diagnosed among younger, less educated, black
women of poor socioeconomic status. Hence, it is argued that the predictors of PE may correspond
to the same predictors of low 25(OH)D status, leading to a biased sample population. Furthermore,
the reliability of these results are questionable, as serum 25(OH)D was measured over 40 years after
completion of the study [58].
3.2.2. Vitamin D Intake and Preeclampsia
We found only one large prospective cohort that described vitamin D intake in relation to PE.
Analysis of vitamin D intakes from over 23,000 nulliparous women participating in the Norwegian
Mother and Child Cohort Study [60] found a lower total vitamin D intake was associated with an
increased risk of developing PE. Compared to non-supplement users, women taking a vitamin D
supplement (400–600 IU/day) had a 27% reduced risk of PE, potentially supporting the theory of a
role for vitamin D supplementation in PE prevention, as was discussed earlier [28,30].
3.2.3. Gestational Hypertension
Focusing on gestational hypertension alone, higher plasma 25(OH)D concentrations were
associated with a greater risk of hypertension among 1591 women (16.4–36.9 weeks’ gestation)
participating in Project Viva [61], corresponding to an odds ratio of 1.32 for each 25 nmol/L increment
in 25(OH)D concentration. Though contrary to the current hypothesis, such findings support
the previously-reported association of higher vitamin D intakes with increased risk of gestational
hypertension from this cohort [62]. Nonetheless, a 25 nmol/L increment is substantial in view
of the reported distribution of 25(OH)D in the Project Viva cohort and among pregnant women
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elsewhere [17,39]. In a much smaller sample (n = 75), the prospective cohort of mother-infant dyads by
Hossain and colleagues [38], that acknowledged vitamin D status as an independent predictor of PE,
also identified maternal 25(OH)D concentration at delivery as an inverse independent predictor of
mean arterial pressure, for which, again, the findings are confined to a specific, vulnerable population.
Similar caution should be applied to the large (n = 1000) cross-sectional study by Al-Shaikh [63],
in which there was also a high prevalence of low vitamin D status (86%), and where hypertensive
disorders were not seen among women presenting with a 25(OH)D concentration ≥75 nmol/L at
delivery. Furthermore, the frequency of PIH did not differ significantly between those with or without
low vitamin D status and the fact that over half (57%) the study population were classified as obese
upon admission to antenatal care, coupled with an extremely low incidence of PE (<1%), raises
concerns as to whether additional cases of PE may have been misdiagnosed or undetected. Irrespective
of sample size (n ranged from 48 to 263) and diversity of the populations studied, case-control studies
stratified by maternal vitamin D status [52], total vitamin D intake [52,64,65], or supplement use [55,64],
do not report effects on blood pressure or PIH development.
A summary of observational studies that assessed the risk of gestational hypertensive disorders
with serum 25(OH)D status or maternal vitamin D intake is provided in Tables 1 and 2, respectively.
For ease of understanding, an overview of recent systematic reviews that have explored this topic is
provided in Table 3.
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Table 1. Observational studies of serum 25(OH)D and risk of hypertensive disorders in pregnancy.
Author Year Design n Gestational Age Outcome SignificantAssociation
Abedi [55] 2014 Case-control 118 Delivery Risk of PE was higher at 25(OH)D concentrations <25 nmol/L (OR 24.04, 95% CI: 2.1, 274.8) Yes
Achkar [40] 2015 Nested case-control 2144 <20 weeks Risk of PE was higher at 25(OH)D concentrations <30 nmol/L compared to >50 nmol/L(OR 2.23, 95% CI: 1.29, 3.83) Yes
Al-Shaikh [63] 2016 Cross-sectional 1000 Delivery PIH was not seen at 25(OH)D concentrations ≥75 nmol/L but frequency of PIH wasnot significant No
Álvarez-Fernández
[44]
2015 Retrospective cohort 257 9–12 & 20–41weeks
Risk of late onset PE was higher at 25(OH)D concentrations <50 nmol/L
(OR 4.6, 95% CI: 1.4, 15) Yes
Anderson [52] 2015 Case-control 48 First trimester 25(OH)D concentrations did not differ between preeclamptic/hypertensive andnormotensive women No
Bärebring [35] 2016 Prospective cohort 2000 First & thirdtrimester
An increase in 25(OH)D of ≥30 nmol/L was associated with lower odds of PE
(OR 0.22, 95% CI: 0.084, 0.581) but not PIH alone Yes
Bodnar [58] 2014 Case-cohort 3703 ≤26 weeks Risk of severe PE was lower at 25(OH)D concentrations >50 nmol/L(RR 0.65, 95% CI: 0.43, 0.98) Yes
Bomba-Opon [43] 2014 Prospective cohort 289 First trimester 25(OH)D concentrations were not related to early biomarkers of PE No
Burris [61] 2014 Prospective cohort 1591 16.4–36.9 weeks Higher 25(OH)D concentrations were associated with a greater risk of hypertension(OR 1.32 for per 25 nmol/L increment, 95% CI: 1.01, 1.72) Yes
Gidlöf [49] 2015 Nested case-control 159 12 weeks 25(OH)D concentrations <50 nmol/L was not associated with PE No
Hossain [38] 2011 Prospective cohort 75 Delivery
Women with 25(OH)D concentrations in the lowest vs. highest tertile were more likely to
develop hypertension (OR 3.38, 95% CI: 0.40, 28.37) and/or PE (OR 2.28, 95% CI: 0.35,
23.28); ≤50 nmol/L was identified as the risk threshold
Yes
Kiely [39] 2016 Prospective cohort 1768 15 weeks Risk of PE and small for gestational age combined was lower at 25(OH)D concentrations≥75 nmol/L (OR 0.64, 95% CI: 0.43, 0.96) Yes
Lechtermann [51] 2014 Nested case-control 63 Delivery Mean ± SD summertime 25(OH)D status was lower in women with than without PE(45 ± 43 vs. 123 ± 73 nmol/L) Yes
Mohaghegh [56] 2015 Case-control 91 Delivery Mean ± SD 25(OH)D status was lower in women with than without PE(38 ± 34 vs. 58 ± 38 nmol/L) Yes
Pena [54] 2015 Cross-sectional 179 Delivery Preeclamptic mothers had a higher rate of 25(OH)D <50 nmol/L than those without PE(50% vs. 23%) Yes
Ringrose [64] 2011 Case-control 187 Delivery
Hypertensive women had lower mean ± SD 25(OH)D concentrations compared with
controls (62 ± 26 vs. 70 ± 29 nmol/L) in the univariate analysis but not when controlled
for BMI
No
Robinson [53] 2013 Case-control 80 Diagnosis(28+ weeks)
Median 25(OH)D concentrations were lower in women with EOSPE than in controls
(42 vs. 83 nmol/L) Yes
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Table 1. Cont.
Author Year Design n Gestational Age Outcome SignificantAssociation
Schneuer [50] 2014 Nested case-control 5109 10–14 weeks 25(OH)D status was not a predictor of PE No
Scholl [41] 2013 Prospective cohort 1141 <20 weeks Women with secondary hyperparathyroidism had a >2-fold increased risk of PE when25(OH)D concentrations were <50 nmol/L (95% CI: 1.23-, 6.41-fold) Yes
Shand [37] 2010 Prospective cohort 221 10–20 weeks 25(OH)D status was not related to PE No
Singla [59] 2015 Case-control 174 NS (mean35–36 weeks)
Mean ± SD 25(OH)D status was lower in women with than without PE
(24 ± 12 vs. 37 ± 17 nmol/L) Yes
Wei [36] 2012 Prospective cohort 697 12–18 & 24–26weeks
25(OH)D concentrations <50 nmol/L at 24–26 weeks were associated with increased risk of
PE (OR 3.24, 95% CI: 1.37, 7.69) Yes
Wei [42] 2013 Prospective cohort 697 12–18 & 24–26weeks PlGF levels were lower in women with 25(OH)D concentrations <50 nmol/L Yes
Wetta [58] 2014 Nested case-control 300 15–21 weeks 25(OH)D status in early pregnancy was not related to PE at <37 weeks’ gestation No
Woodham [45] 2011 Nested case-control 164 15–20 weeks For each 10 nmol/L increase in 25(OH)D, risk of severe PE decreased by 38%(95% CI: 0.51, 0.76) Yes
Xu [47] 2014 Nested case-control 200 ≥24 weeks Risk of PE quadrupled when 25(OH)D concentrations were <37.5 nmol/L(OR 4.2, 95% CI: 1.4, 12.8) Yes
Ullah [57] 2013 Case-control 188 >20 weeks Risk of eclampsia and PE was higher at 25(OH)D concentrations <75 nmol/L(OR 5.14, 95% CI: 1.98, 13.37 and OR 3.9, 95% CI: 1.18, 12.87, respectively) Yes
Zabul [46] 2015 Nested case-control 74 Late gestation 25(OH)D status did not significantly differ between preeclamptic andnon-preeclamptic women No
BMI, body mass index; CI, confidence interval; EOSPE, early onset severe preeclampsia; NS, not specified; OR, odds ratio; PE, preeclampsia; PIH, pregnancy-induced hypertension; PlGF,
placental growth factor; RR, risk ratio.
Table 2. Observational studies of dietary vitamin D intake and risk of hypertensive disorders in pregnancy.
Author Year Design n Gestational Age Outcome Significant Association
Abedi [55] 2014 Case-control 118 Delivery Vitamin D supplement use did not differ between preeclamptic and non-preeclamptic women No
Anderson [52] 2015 Case-control 48 First trimester Dietary vitamin D intake did not differ between hypertensive and normotensive women No
Haugen [60] 2009 Prospectivecohort 23,423 15, 22 & 30 weeks
Women taking a vitamin D supplement (400–600 IU/day) had a reduced risk of PE compared to
non-users (OR 0.73, 95% CI: 0.58, 0.92) Yes
Kazemian [65] 2013 Case-control 263 21–35 weeks Vitamin D intake was not associated with risk of gestational hypertension No
Oken [62] 2007 Prospectivecohort 1718 First trimester
Women with higher vitamin D intakes had an increased risk of gestational hypertension
(OR 1.11 per 100 IU, 95% CI: 1.01, 1.21) Yes
Ringrose [64] 2011 Case-control 187 Delivery Vitamin D intake (diet + supplements) did not differ between hypertensive and normotensive women No
OR, odds ratio; CI, confidence interval; PE, preeclampsia.
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Table 3. Summary of recent systematic reviews examining the relationship of maternal vitamin D status and/or intake and risk of preeclampsia.
Author Year Design of Studies Number ofStudies
Sample
Size
Meta-Analysis
(Yes/No) Outcome
Association
(Yes/No)
De-Regil [28] 2016 Randomisedcontrolled trials 2 219 Yes
Relative to placebo, a ‘trend’ in the risk reduction of PE was seen among gravidae
consuming supplemental vitamin D 1 (8.9% vs. 15.5%; average risk ratio 0.52; 95%
CI: 0.25, 1.05)
Yes
De-Regil [28] 2016 Randomisedcontrolled trials 3 1114 Yes
Combined supplementation of vitamin D 1 plus calcium resulted in a reduced risk
of PE (5% vs. 9%; average risk ratio 0.51; 95% CI: 0.32, 0.80)
Yes
Arain [66] 2015 Intervention &observational 7 26,924 No
Risk of PE may be increased at lower levels of 25(OH)D (range < 37.5–75 nmol/L),
but the relationship between vitamin D and PE is conflicted by large heterogeneity
between studies
Yes
Harvey [67] 2014 Intervention &observational 12 642 Yes
Meta-analysis of 4 observational studies found the risk of PE did not increase with
decreased vitamin D status 1 (pooled OR 0.75, 95% CI: 0.48, 1.19) No
Aghajafari [26] 2013 Observational 9 3191 Yes PE was significantly associated with 25(OH)D concentrations <50 nmol/L(pooled OR 1.79, 95% CI: 1.25, 2.58) Yes
Hyppönen [30] 2013 Randomised trials 4 5982 Yes Women receiving supplemental vitamin D
1 had a reduced risk of PE compared to
controls (pooled OR 0.66, 95% CI: 0.52, 0.83)
Yes
Hyppönen [30] 2013 Prospectiveobservational 6 6864 Yes
Mothers with higher serum 25(OH)D status 1 had a reduced risk of PE
(pooled OR 0.52, 95% CI: 0.30, 0.89)
Yes
Hyppönen [30] 2013 Prospectiveobservational 2 77,165 Yes
Mothers receiving supplemental vitamin D 1 in early pregnancy had lower odds of
developing PE (pooled OR 0.81, 95% CI: 0.75, 0.87)
Yes
Tabesh [27] 2013 Observational 15 3007 Yes
Eight studies (2485 women) were included in the meta-analysis, for which PE was
significantly correlated with 25(OH)D concentrations <50 nmol/L but not
<38 nmol/L
Yes
Wei [29] 2013 Observational 8 2273 Yes Risk of PE was increased at 25(OH)D concentrations <50 nmol/L(OR 2.09, 95% CI: 1.50, 2.90) Yes
Christesen [68] 2012 Observational 9 24,704 No
Risk of PE was inversely associated with a vitamin D intake of ≥400–600 IU/day
and/or status ≥37.5–80 nmol/L in studies where the number PE cases exceeded 40
but no association was found in studies with <40 cases of PE
Yes
Thorne-Lyman
& Fawzi [69] 2012
Intervention &
observational 7 NS Yes
Pooled analysis of 2 studies, (>25,000 women), found no difference PE risk when
stratified by highest and lowest categories of total vitamin D intake 1
(OR 0.95, 95% CI: 0.86, 1.06)
No
Nassar [70] 2011 Nestedcase-control 2 435 No
Sufficient evidence was not available to firmly established an association between
first trimester 25(OH)D status and PE risk No
1 Vitamin D dose range or status as defined in each included study. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; NS, not specified; PE, preeclampsia; OR, odds ratio.
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4. Discussion
At present, there is insufficient evidence to justify setting dietary vitamin D recommendations
based on the avoidance of gestational hypertensive disorders alone. However, this review supports
the findings from two recent meta-analyses of observational studies that have shown a significant
association between vitamin D deficiency and PE risk [26,27]. Notwithstanding the controversy
regarding appropriate 25(OH)D cut-off points for vitamin D deficiency, both meta-analyses observed a
significant correlation when deficiency was defined as 25(OH)D concentrations <50 nmol/L [26,27].
Of note is that, in the subgroup analysis reported by Tabesh [27], the inverse relationship was significant
for studies conducted in the United States only, suggesting the vitamin D-PE interaction may be
region-specific and reiterates the need for consideration of variation in latitude and ethnicity in vitamin
D association studies.
We identified several challenges in our interpretations. In terms of study design, vitamin D
status is often only evaluated at a single time point throughout gestation, frequently in the late second
or third trimester, when it may be too late to intervene. It is likely that 25(OH)D measurements
throughout each trimester would give a clearer understanding of any potential cause and effect
relationship [48] and the most effective strategy for intervention. Furthermore, if 25(OH)D is measured
following PE diagnosis, reverse causality cannot be discounted, and the results, therefore, offer limited
clinical utility. In addition to analytical differences, the lack of consensus regarding a 25(OH)D cut-off
to define vitamin D sufficiency hampers international comparisons of deficiency prevalence and
subsequent risk of adverse health outcomes, including PE and gestational hypertension. 25(OH)D
data must be reported across all studies using a range of thresholds to facilitate cross-comparison
between populations. Based on a 25(OH)D-PE risk curve, a concentration of <50 nmol/L has been
suggested [36]. However, specific threshold values at which the risk of PIH is increased may vary
based on certain physiological attributes, including BMI, race, and gestational age, all of which may
interfere with vitamin D status. It is, therefore, plausible that a range, rather than a specific cut-off
point, for 25(OH)D exists in which women are less likely to develop PIH.
To date, a lack of evidence from long-term, high-dose vitamin D supplementation trials
undermines our confidence around potential adverse effects associated with the prolonged use of
high-dose vitamin D supplements [71]. However, obtaining trial data to specifically assess the risk
of adverse outcomes at high concentrations is ethically challenging and likely requires an individual
participant level (IPD)-analysis approach of past intervention trials with safety outcomes. In light of the
increased risk of hypertension among women in Project Viva [61,62], and the uncertainty surrounding
the concentration at which risk of hypercalcaemia increases, caution should be urged with regards to
dosing, especially in pregnancy.
Our analysis of the literature clearly identifies the need to conduct a large dose-response RCT,
considering race, season and background diet, including calcium intake, to determine whether
improved vitamin D status will help protect against PIH. Implementation of such a trial must consider
the dose-response relationship of serum 25(OH)D to total vitamin D intake [18]. In the absence of
pregnancy-specific values, regulatory agencies currently recommend a minimum vitamin D intake of
400 IU/day [11,72] sufficient to protect against maternal deficiency at a threshold of 25–30 nmol/L,
but this will not protect against neonatal deficiency at the same threshold [73]. It is now likely that
ethical review boards may no longer approve a true placebo group in pregnancy trials with vitamin D,
meaning future intervention studies might be required to screen at baseline for deficiency [74] or
supplement a ‘low’ intake group, resulting in a minimum 25(OH)D concentration range of≥30 nmol/L.
For outcomes such as PIH, and PE in particular, where narrow ranges of 25(OH)D concentrations
could be pivotal to determining a reduction in incidence rates, the absence of a true placebo group
may pose further experimental challenges [18].
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5. Conclusions
This review critically evaluates the current evidence for an association between vitamin D status
and/or intake and risk of hypertensive disorders in pregnancy. The inclusion of both observational
and interventional studies helped to avoid potential oversight in the published research as the limited
quantity of data produced by interventional studies alone may limit our understanding of the state of
the art with regard to vitamin D and PIH. While most studies report serum 25(OH)D concentrations,
we also reported studies of maternal vitamin D intakes to ensure a comprehensive analysis. Another
strength of this review is that it reports outcomes relating to all terms of PIH and is not limited to
PE. Systematic reviews to date have been unable to draw firm conclusions regarding the potential of
vitamin D to protect against gestational hypertensive disorders. Evidence from RCTs are limited to PE
prevention and the current evidence base is weak and subject to a high risk of bias. Data from trials
using combined vitamin D and calcium supplementation support a protective effect against PE among
the supplemented groups. Observational cohort studies show a positive association between vitamin D
deficiency and increased risk of PE, but results are hampered by suboptimal clinical phenotyping,
incomplete subject characterisation and large heterogeneity between studies. Estimates of vitamin D
intakes in observational studies are usually absent and, in those that report exposure levels, the
overwhelming effect of micronutrient supplementation on vitamin D intakes opens the possibility
of confounding by other nutrients. In light of evidence for a mechanistic role for vitamin D in the
metabolic adaptation of healthy pregnancy, it is biologically plausible that the dysregulated metabolite
concentrations in unhealthy pregnancies (including PE) may, in part, result from a deficiency in
vitamin D [15]. We, therefore, extend the view expressed by several investigators, who stress a need for
an adequately-powered, well-conducted RCT to establish a causal effect between vitamin D deficiency
and increased risk of PE.
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